Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET. Company Participants. Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executiv ...

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device ...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final two rounds ...

For decades, FDA’s Center for Devices and Radiological Health (CDRH) has been recognizing standards that can be referenced in premarket medical ...

The Invisalign® Palatal Expander, launching in the UAE markets today, November 4, 2024, offers a revolutionary approach to ...

Royal Philips announced enrollment of the first patient in THOR, a United States investigational device exemption (IDE) clinica ...

Akura Medical, a Shifamed portfolio company, announced today that the FDA granted its Katana system investigational device exemption (IDE).

The trial is anticipated to commence in Q1 2025 and will enrol 264 subjects at up to 60 clinical sites worldwide.

Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced today the US Food and Drug Administration has approved its ...

R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its drug-eluting ...

The R3 Vascular investigational device exemption will be used to launch a pivotal trial of its treatment for peripheral arterial disease.